TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27469482
Drug: NT‐proBNP guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP guided therapy (goal NT‐proBNP <1000 pg/mL)
Study: 24023318
Drug: 5‐fluorouracil (5‐FU)/l‐leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU)/l‐leucovorin (LV)/CPT‐11 (FOLFIRI) regimen
Study: 12975721
Drug: Low-dose diuretics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, dihydropyridine calcium antagonists
Study: 22658300
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Study: 12975721
Drug: Multiple antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple antihypertensive drugs
Study: 9380472
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension 15 mg/kg
Study: 24824648
Drug: AS03A-adjuvanted H1N12009
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose)
Study: 24824648
Drug: AS03A-adjuvanted H1N12009
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose plus booster)
Study: 12056293
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d sulfasalazine
Study: 10692750
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (750 mg b.d.)
Study: 10692750
Drug: Amoxycillin/clavulanate (875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (875/125 mg b.d.)
Study: 1768223
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen oral contraceptive pills
Study: 6790206
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg, i.v. administration)
Study: 26121830
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid therapy
Study: 26121830
Drug: Postauricular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postauricular steroid therapy
Study: 19805701
Drug: Oral naltrexone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone, 50 mg/d for 6 months (plus placebo implants)
Study: 19805701
Drug: Naltrexone implant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone implant, single dose of 2.3 g (plus placebo tablets)
Study: 9649989
Drug: droperidol 0.05
Normalized name: fentanyl citrate/droperidol 0.05-2.5MG INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.05 mg
Study: 9649989
Drug: droperidol 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.10 mg
Study: 9649989
Drug: droperidol 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.15 mg
Study: 9649989
Drug: droperidol 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.20 mg
Study: 7853676
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 20 mg/kg administered via intravenous bolus injection or 30‐minute intravenous drip infusion 3 times daily for 3‐11 days
Study: 7853676
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 20 mg/kg
Study: 26056119
Drug: TCZ-SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-SC 162 mg weekly + placebo-IV every four weeks
Study: 26056119
Drug: TCZ-IV 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-IV 8 mg/kg every four weeks + placebo-SC weekly
Study: 26056119
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who switched formulations
Study: 23342783
Drug: Umbilicus moxibustion
Normalized name: Umbilicus rupestris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilicus moxibustion therapy plus Jingui Shenqi Pill (8 pills, 3 times a day)
Study: 23342783
Drug: Jingui Shenqi
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jingui Shenqi Pill (8 pills, 3 times a day)
Study: 16043683
Drug: Enalapril maleate,
Normalized name: Enalapril Maleate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril maleate, 5 to 40 mg/d
Study: 11377599
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m², day 1) and cisplatin (80 mg/m², day 2)
Study: 11377599
Drug: Gemcitabine (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1100 mg/m², days 1 and 8) and docetaxel (100 mg/m², day 8)
Study: 2529776
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic hormone (ANH) infusion at 0.47 pmol.kg‐1.min‐1 for 2.5 hours
Study: 28011387
Drug: Immediate intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intensive non-surgical periodontal treatment
Study: 28011387
Drug: Rescue treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment with delayed intensive treatment
Study: 25195169
Drug: Anakinra (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (1 mg/kg, maximum 100 mg)
Study: 21507295
Drug: TNF‐α treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α treatment (1.0 ng/mL)
Study: 26275480
Drug: TNF‐α treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α treatment
Study: 17105853
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg etanercept (ETN)
Study: 17105853
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg etanercept (ETN)
Study: 15629872
Drug: Reboxetine 8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 8 mg/day
Study: 28478996
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone, olanzapine, quetiapine)
Study: 30653856
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) supplementation (280 mL/d for 8 days)
Study: 28223259
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AED) administered from 4 days before surgery until 1 month after surgery
Study: 25060406
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (100 to 1600 mcg) during a 26-day open-label titration period
Study: 26509361
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray
Study: 19934866
Drug: Milrinone (phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (phosphodiesterase 3 inhibitor)
Study: 3505192
Drug: 1 alpha
Normalized name: antiCD11 alpha
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 alpha (OH)D3 + Ca 1.0 g/day
Study: 3505192
Drug: Ca 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca 1.0 g/day
Study: 29016275
Drug: Psychoanalytic-Interactional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic-Interactional Therapy (PIT)
Study: 26808580
Drug: Expert Psychodynamic
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert Psychodynamic Therapy (E-PDT)
Study: 26808580
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (treatment as usual/waiting for treatment)
Study: 22750188
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) self‐help volume
Study: 10205101
Drug: Adrenaline 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.25 ml (1:1000)
Study: 16206598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol and analapril with trimetazidine (70 mg/day for 6 months)
Study: 16206598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol and analapril
Study: 8527283
Drug: TRH 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH 0.5 mg
Study: 8527283
Drug: TRH 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH 1.0 mg
Study: 8527283
Drug: RX77368 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX77368 1 mg
Study: 1730831
Drug: Oral provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral provocation with alpha-amylase
Study: 27154462
Drug: MedSentry remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedSentry remote medication monitoring system
Study: 19724055
Drug: Deferasirox (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (35 mg/kg single dose)
Study: 17710426
Drug: Isotretinoin daily
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin daily for the first month, then first 10 days of each month for 5 months (group 2)
Study: 17710426
Drug: Isotretinoin daily
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin daily for 6 months (group 3)
Study: 11495074
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of lansoprazole once daily for 5 days
Study: 9778202
Drug: ACE-I treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I treatment
Study: 9778202
Drug: No ACE-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE-I treatment
Study: 2407872
Drug: Diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem SR monotherapy
Study: 9649912
Drug: Hydrochlorothiazide monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide monotherapy
Study: 2407872
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Diltiazem SR + Hydrochlorothiazide)
Study: 4064778
Drug: Bovine heparin
Normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine heparin
Study: 4064778
Drug: Porcine heparin
Normalized name: Porcine heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine heparin
Study: 7404480
Drug: Bovine heparin
Normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine heparin and Porcine heparin
Study: 31758080
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific regimen not detailed)
Study: 14970894
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar pharmacological treatments)
Study: 7004956
Drug: Dantrolene sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene sodium suspension
Study: 25475771
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) treatment
Study: 20144497
Drug: Non-PRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PRF treatment (control)
Study: 18032083
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered in the morning
Study: 15309229
Drug: Late phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late phototherapy (started when transcutaneous bilirubin reached 8 mg/dl, suspended when bilirubin fell to 5 mg/dl)
Study: 11557835
Drug: Bupropion (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (100 mg/d with gradual increase to 200 mg twice daily)
Study: 9631781
Drug: Early extubation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early extubation (EE) with reduced dose of fentanyl (15 microg/kg)
Study: 8187295
Drug: Levothyroxine 0.1
Normalized name: LEVOTHYROXINE 0.1MG/ML ORAL SOLN UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine 0.1 mg daily (Group A)
Study: 9882992
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group B)
Study: 2886820
Drug: Intravenous dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dihydroergotamine (DHE)
Study: 31206358
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (rosuvastatin)
Study: 26632101
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan Medoxomil (AZL-M) 20, 40, and 80 mg QD
Study: 26632101
Drug: Chlorthalidone (CLD)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (CLD) 12.5 and 25 mg QD
Study: 23329787
Drug: Enteral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L-arginine supplementation (1.5 mmol/kg/d bid)
Study: 21119151
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for personality disorders (CBT-PD)
Study: 19066155
Drug: Ti6A17Nb-alloy (girotan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ti6A17Nb-alloy (girotan L)
Study: 14604568
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, 15 microg of each protein given at first and second injection (4 weeks apart)
Study: 14604568
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, No sulphadoxine-pyrimethamine (SP)
Study: 14604568
Drug: SP+vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP+vaccine
Study: 30265039
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) for attending treatment for 6 weeks
Study: 30265039
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) for attending treatment for 7-12 weeks
Study: 11952542
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate at a dose of 10 mg kg(‐1) daily up to 600 mg day(‐1)
Study: 9861126
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg with Droperidol 1.25 mg
Study: 7624737
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 6 g daily (6 enterosoluble tablets of 500 mg AA, twice a day)
Study: 7624737
Drug: Placebo (tartaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tartaric acid, TA) 2.55 g daily (213 mg TA, twice a day)
Study: 2151405
Drug: Triptorelin (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.2 mg monthly for 6 months)
Study: 2151405
Drug: Buserelin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (900 micrograms daily for 6 months)
Study: 360561
Drug: Cefadroxil 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1,000 mg. twice daily
Study: 360561
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg. four times a day
Study: 31177906
Drug: Selective ETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective ETA receptor antagonist, sitaxentan
Study: 28655128
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping along with conventional treatment
Study: 21795455
Drug: 0.08 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg/kg metreleptin (n = 11)
Study: 21795455
Drug: 0.01, 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d
Study: 17453095
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of one percent phenol and one percent menthol, twice a day for six weeks
Study: 11212050
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with naloxone (0.208 microg x kg(‐1) x hr(‐1))
Study: 11212050
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine without naloxone (control group)
Study: 11212050
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with naloxone
Study: 9390113
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg dexamethasone
Study: 9390113
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg dexamethasone
Study: 7816418
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg digitoxin per day
Study: 23465178
Drug: Follow-up testing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up testing after a PSA level result of >10 ng/mL
Study: 23465178
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a urologist after a PSA level result of >4 ng/mL
Study: 21349239
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg once daily plus pipamperone 5 mg twice daily (PipCit)
Study: 19916992
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose of nelfinavir (1250 mg q12h for 3.5 days)
Study: 19916992
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of nelfinavir (1250 mg q12h for 3 days and single dose of 3125 mg on day 4)
Study: 17299467
Drug: Test yoghurt
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test yoghurt containing GOS (12 g/day), prunes (12 g/day) and linseed (6 g/day)
Study: 14618095
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of amlodipine (5 mg initially, titrated to 10 mg if diastolic BP >= 90 mm Hg)
Study: 14618095
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of amlodipine
Study: 11009051
Drug: Normal-strength grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-strength grapefruit juice (200 ml)
Study: 11009051
Drug: Double-strength grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-strength grapefruit juice (200 ml)
Study: 11009051
Drug: Multiple-dose double-strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose double-strength grapefruit juice (three times daily)
Study: 1395911
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 to 80 mg daily for 3 months)
Study: 6118074
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg/kg
Study: 2869713
Drug: Pancuronium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.05 mg/kg and 0.08 mg/kg
Study: 29110109
Drug: MRI-based Kellgren
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-based Kellgren and Lawrence (K&L) grading
Study: 20586860
Drug: Sofalcone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofalcone (300 mg/day)
Study: 8931684
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate 1.8 mg/kg
Study: 8708713
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate 2.4 mg/kg
Study: 26191966
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention plus guideline-level care
Study: 20203161
Drug: Methylprednisolone 500
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500 mg intravenously
Study: 17095134
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HHS) 2 ml/kg/10 min (7.2% NaCl with 6% hydroxy ethyl starch 200,000/0.5)
Study: 10506878
Drug: Pristinamycin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin, 1 g b.i.d.
Study: 10506878
Drug: Amoxicillin/clavulanic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid, 500 mg x 4/d
Study: 3095082
Drug: Ritanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 10 mg
Study: 24016559
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and hormone
Study: 24016559
Drug: Ginaton and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton and hormone
Study: 19141586
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg)
Study: 19141586
Drug: RU38486 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU38486 (400 mg)
Study: 19141586
Drug: Combined spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined spironolactone (200 mg) + RU38486 (400 mg)
Study: 10942064
Drug: CMB-401 (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMB-401 (dosing commenced at 2 mg/m2 and progressed to 16 mg/m2 over seven cohorts)
Study: 8843892
Drug: Pravastatin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (15 mg) for 12 months
Study: 6565475
Drug: Single-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose amoxicillin